Oncomark

Biotechnology, Health Diagnostics, Medical
Founded in 2007-01-01
Dublin, Dublin, Ireland
http://www.oncomark.com
For Profit

About Oncomark

OncoMark is a UCD spin-out that develops companion diagnostic tests to support cancer drug development. Companion diagnostics allow pharmaceutical companies to select patients for which a drug may be particularly effective (patient stratification). The test can also be used during clinical trials to help reduce the numbers of patients required to complete a clinical trial and its duration, while also increasing the likelihood that the trial will be successful. The end result is improved outcome for cancer patients. The company has a portfolio of diagnostic tests in development, covering some of the key cancer types (breast, colorectal, prostate, melanoma), supported by €3.9m in EU R&D funding. There are currently 12 employees funded through 6 grants. The company was founded by Prof. William Gallagher in UCD and is led by Dr. Mairin Rafferty, the CEO/COO. The company has a strong advisory board, which includes Prof. John Crown and Prof. Bryan Hennessy.

Company Metrics

  • Employees: 11-50
  • Monthly Visits: None
  • Tech Stack: 9 active products

Financial Information

  • Estimated Revenue: $1M to $10M
  • Total Funding: 4851250 EUR
  • Last Funding: None (Venture - Series Unknown)
  • Funding Status: M&A

Technology Stack

Oncomark actively uses 9 products in their tech stack.

Market Presence

Industries: Biotechnology, Health Diagnostics, Medical

Headquarters: Dublin, Dublin, Ireland